Seung Hwan Moon
성균관대학교 의과대학 · 의학
Seung Hwan Moon 교수의 연구실은 정밀의료를 목표로 PET/CT 영상 기반의 대사적 생체지표를 활용한 암 진단 및 예후 평가에 중점을 두고 있습니다. 특히, 대표적인 대사량인 총 병변 당량(TLG)과 표준화된 집합량(SUV max)을 활용해 편도판암, 비부비동 림프종, 난소암 등 다양한 암 종양의 생존율과 치료 반응을 정량적으로 평가하고 있습니다. 또한 NAFLD와 동맥염 등의 대사성 질환과 암의 연관성에 대해서도 영상 생물학적 관점에서 탐구하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Accurate prediction of cancer prognosis before the start of treatment is important since these predictions often affect the choice of treatment. Prognosis is usually based on anatomical staging and other clinical factors. However, the conventional system is not sufficient to accurately and reliably determine prognosis. Metabolic parameters measured by (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET) have the potential to provide valuable information regarding prognosis and treat
TLG is a significant independent metabolic prognostic factor for overall survival in patients with SCC of the tonsil.
Our study demonstrated that (18)F-FDG PET/CT scanning is a valuable modality for staging and treatment planning in patients with nasal-type NK/T-cell lymphoma.
We assessed the association between nonalcoholic fatty liver disease (NAFLD) and carotid artery inflammation measured by (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography. Participants were 755 consecutive otherwise healthy adult males who underwent a general health screening program. Carotid FDG uptake, represented as maximum target-to-background ratio, was increased with mild (n = 237; 1.61 ± 0.14; P = .033) and moderate NAFLD (n = 145; 1.63 ± 0.16; P = .005) comp
The TLG of the primary tumor was a significant independent metabolic prognostic factor of DFS in patients with NPC treated with CCRT.
SUV max, combined with clinical T classification, may be useful for predicting occult lymph node metastasis in patients with clinically N0 squamous cell carcinoma of the esophagus.
This study investigated the associations between image features extracted from tumor <sup>18</sup>F-fluorodeoxyglucose (FDG) uptake and genetic alterations in patients with lung cancer. A total of 137 patients (age, 62.7 ± 10.2 years) who underwent FDG positron emission tomography/computed tomography (PET/CT) and targeted deep sequencing analysis for a tumor lesion, comprising 61 adenocarcinoma (ADC), 31 squamous cell carcinoma (SQCC), and 45 small cell lung cancer (SCLC) patients, were enrolled
